One-Year Study of Clinical Cardiotoxicity Follows Anthracyclin Treatment in Childhood Malignancy at Benghazi Children Hospital

Najat Elrugige, Muna Mustafa Ali, Mohamed Masoud Alferjani
{"title":"One-Year Study of Clinical Cardiotoxicity Follows Anthracyclin Treatment in Childhood Malignancy at Benghazi Children Hospital","authors":"Najat Elrugige, Muna Mustafa Ali, Mohamed Masoud Alferjani","doi":"10.36347/sjams.2023.v11i09.012","DOIUrl":null,"url":null,"abstract":"Background: Treatment of pediatric malignancy has greatly improved and survival according to SEER data, mortality rate declined by 40 percent between 1975 and 1995. This declined in mortality has accompanied by increase in the recognition of long term side effect from treatment of childhood cancer, one of major complication is cardiac, during or after administration of anthracyclin patient can develop acute cardiac toxicity. Aim: To determine the incidence of clinical cardiotoxicity from anthracycline chemotherapy in children with cancer and to identify risk factors. Material and Method: One-year study (2021) to children with cancer were received anthracycline as part of chemotherapy at Children Hospital Benghazi. Results: During the study period one year (Jan.2021- Dec. 2021) 51 cases received anthracyclin as part of chemotherapy were evaluated with echocardiography there is male predominance represented 62.7% & females37.3%, M: F 1.6:1, Age range from 5 months to 14 years, the commonest age group 1-5 years around 25cases represented 49%, Most cases evaluated in our study diagnosed with Acute Lymphoblastic Leukemia (ALL) 24 cases represented 47.1%, 9 cases with Acute Myeloid Leukemia (AML) 17%, Lymphoma 7 cases represented 13,7%, wilm’s tumor 5 cases 9.8%, neuroblastoma 3 cases 5.8%, Each of Retinoblastoma, adrenocortical carcinoma and hepatoblastoma 1 case (2%), 34 cases were evaluated still on treatment 66.7%, 17 cases 33.3% were finished treatment on follow up 29 cases were received treatment for less than or equal to one year represented to 56.9%, while 22 cases 43.1% >1year, We were divided the patient according to type of anthracyclin (Adriamycin or douanomycin) results show those received Adriamycin only 39.2%, cases were received douanomycin 7.8%, while cases received both of them 53%, 35.9 % of cases received total doses between 201-250 mg\\ S.A of anthracyclin, 25 cases 32.1% were received less than 100 mg\\S. A, Echocardiography finding were normal .....","PeriodicalId":471520,"journal":{"name":"Scholars journal of applied medical sciences","volume":"2 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scholars journal of applied medical sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36347/sjams.2023.v11i09.012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Treatment of pediatric malignancy has greatly improved and survival according to SEER data, mortality rate declined by 40 percent between 1975 and 1995. This declined in mortality has accompanied by increase in the recognition of long term side effect from treatment of childhood cancer, one of major complication is cardiac, during or after administration of anthracyclin patient can develop acute cardiac toxicity. Aim: To determine the incidence of clinical cardiotoxicity from anthracycline chemotherapy in children with cancer and to identify risk factors. Material and Method: One-year study (2021) to children with cancer were received anthracycline as part of chemotherapy at Children Hospital Benghazi. Results: During the study period one year (Jan.2021- Dec. 2021) 51 cases received anthracyclin as part of chemotherapy were evaluated with echocardiography there is male predominance represented 62.7% & females37.3%, M: F 1.6:1, Age range from 5 months to 14 years, the commonest age group 1-5 years around 25cases represented 49%, Most cases evaluated in our study diagnosed with Acute Lymphoblastic Leukemia (ALL) 24 cases represented 47.1%, 9 cases with Acute Myeloid Leukemia (AML) 17%, Lymphoma 7 cases represented 13,7%, wilm’s tumor 5 cases 9.8%, neuroblastoma 3 cases 5.8%, Each of Retinoblastoma, adrenocortical carcinoma and hepatoblastoma 1 case (2%), 34 cases were evaluated still on treatment 66.7%, 17 cases 33.3% were finished treatment on follow up 29 cases were received treatment for less than or equal to one year represented to 56.9%, while 22 cases 43.1% >1year, We were divided the patient according to type of anthracyclin (Adriamycin or douanomycin) results show those received Adriamycin only 39.2%, cases were received douanomycin 7.8%, while cases received both of them 53%, 35.9 % of cases received total doses between 201-250 mg\ S.A of anthracyclin, 25 cases 32.1% were received less than 100 mg\S. A, Echocardiography finding were normal .....
班加西儿童医院蒽环类药物治疗儿童恶性肿瘤1年临床心脏毒性研究
背景:儿童恶性肿瘤的治疗有了很大的改善,生存率根据SEER数据,1975年至1995年间死亡率下降了40%。死亡率的下降伴随着对儿童癌症治疗长期副作用的认识的增加,其中一个主要并发症是心脏,在蒽环类药物治疗期间或之后,患者可能发生急性心脏毒性。目的:了解儿童癌症患者蒽环类药物化疗的临床心脏毒性发生率,并探讨其危险因素。材料与方法:为期一年的研究(2021年),在班加西儿童医院接受蒽环类药物作为化疗的一部分。结果:研究期间(2021年1月- 2021年12月)51例接受蒽环类药物化疗的患者进行超声心动图评估,男性优势占62.7%;females37.3%, M:F 1.6:1,年龄范围为5个月~ 14岁,最常见的年龄组为1 ~ 5岁,约25例占49%,本研究评估的大多数病例诊断为急性淋巴母细胞白血病(ALL) 24例占47.1%,急性髓性白血病(AML) 9例占17%,淋巴瘤7例占13.7%,wilm肿瘤5例占9.8%,神经母细胞瘤3例占5.8%,视网膜母细胞瘤、肾上腺皮质癌和肝母细胞瘤各1例(2%),34例仍在治疗中,占66.7%。在随访中,完成治疗的有17例(33.3%),治疗不足1年的有29例(56.9%),治疗1年的有22例(43.1%),我们将患者按蒽环类药物类型(阿霉素或豆霉素)进行分组,结果显示阿霉素仅占39.2%,豆霉素占7.8%,两者均占53%,总剂量在201 ~ 250mg \ S.A之间的占35.9%。25例(32.1%)给予小于100 mg\S。A、超声心动图示正常.....
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信